Elamipretide

Elamipretide Clinical Studies and Trials - Stealth BioTherapeutics

Programs & Pipeline. Stealth's lead investigational product candidate, elamipretide, is a peptide compound that readily penetrates cell membranes, and targets ...

Elamipretide - Wikipedia

a small mitochondrially-targeted tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH 2 ) that appears to reduce the production of toxic reactive oxygen species and ...

Efficacy and Safety of Elamipretide in Individuals With Primary ...

Elamipretide in individuals with primary mitochondrial myopathy: The MMPOWER-3 randomized clinical trial.

Elamipretide - Friedreich's Ataxia Research Alliance

Elamipretide (aka Bendavia, MPT-131, and SS31) is a tetrapeptide compound being developed by Stealth Therapeutics. It targets the inner mitochondrial ...

Randomized dose-escalation trial of elamipretide in adults with ...

Elamipretide increased exercise performance after 5 days of treatment in patients with PMM without increased safety concerns.

Elamipretide - an overview | ScienceDirect Topics

Elamipretide (MTP-131) is a synthetic tetrapeptide which interacts with cardiolipin in the inner mitochondrial membrane and leads to reduction of mitochondrial ...

Elamipretide - an overview | ScienceDirect Topics

Elamipretide, also known as SS-31, is a synthetic tetrapeptide with the amino acid sequence D-Arg-2′6′-dimethylTyr-Lys-Phe-NH2.

Stealth BioTherapeutics Announces FDA Advisory Committee ...

... elamipretide, the first potential therapy for Barth syndrome. This ultra-rare, progressive disease affects approximately 150 individuals in ...

Elamipretide for Adult Patients with Primary Mitochondrial Disease

Evaluate the safety and efficacy of an investigational drug called "Elamipretide" in adult patients with mitochondrial disease.

Elamipretide (MTP-131, SS-31) | 99.37%(HPLC) - Selleck Chemicals

Elamipretide (MTP-131, SS-31) is a cytochrome c peroxidase inhibitor. Elamipretide improves mitochondrial dysfunction, synaptic and memory impairment ...

Neuroprotective Effects of a Small Mitochondrially-Targeted ...

Elamipretide appears to enhance neural mitochondrial biogenesis regulators and fusion, inactivate neural mitochondrial fission. Moreover, ...

Stealth Biotherapeutics Announces FDA Acceptance of New Drug ...

If approved, this would be the first marketing authorization for elamipretide, a first-in-class mitochondrial targeted therapeutic. Elamipretide ...

The cardiolipin-binding peptide elamipretide mitigates fragmentation ...

Elamipretide, a clinical-stage compound under investigation for diseases of mitochondrial dysfunction, mitigates impairments in mitochondrial structure- ...

elamipretide - Barth Syndrome Foundation

September 6th, 2024: FDA announced that the Cardiovascular and Renal Drugs Advisory Committee has scheduled their meeting to review Stealth Biotherapeutic Inc.' ...

Elamipretide: Uses, Side Effects, Dosage - MedicineNet

Elamipretide is an investigational drug being developed to treat mitochondrial diseases, yet to be approved by the FDA, but has received ...

elamipretide (Pending FDA Approval) - Medscape

Medscape - Mitochondrial myopathy dosing for elamipretide, frequency-based adverse effects, comprehensive interactions, contraindications, ...

Stealth BioTherapeutics - Elamipretide - AdisInsight - Springer

Elamipretide (formerly MTP 131) is a small-molecule, mitochondria-targeting amide, being developed by Stealth BioTherapeutics (formerly Stealth Peptides), ...

Phase 3 Randomized Trial to Evaluate Subcutaneous Elamipretide ...

A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of ...

FDA adcomm ends in favor of Stealth's Barth syndrome drug

The Cardiovascular and Renal Drugs Advisory Committee voted 10-6 supporting Stealth Biotherapeutics' elamipretide for treating Barth syndrome.

Mitochondrial Disease Therapy Elamipretide Is in Clinical Trials...

Elamipretide is designed to restore dysfunctional mitochondria's energy production, saving the cells and reducing organ damage.